Atlas Trials

Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster

Clinical trial NCT05897190 · COMPLETED

Trial details

NCT number
NCT05897190
Sponsor
Argorna Pharmaceuticals Co., LTD
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
SARS-CoV-2
Start date
2022-05-16
Primary completion
2022-06-13
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.